TrialThoracic cancer2022

Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study.

Yukio Hosomi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.